http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
FDA agrees to review Cogent's bezuclastinib application for rare cancer
-
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
-
Cogent Biosciences outlines 2026 milestones for bezuclastinib drug applications
-
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
-
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
-
Cogent Biosciences submits drug application for systemic mastocytosis
-
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
-
Cogent Biosciences reports positive APEX trial results for bezuclastinib
-
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Cogent Biosciences presents full SUMMIT trial results for bezuclastinib
-
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematolog
-
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
-
Cogent Biosciences reports positive phase 3 trial results for GIST treatment
-
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
-
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
-
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
-
Cogent Biosciences presents KRAS inhibitor data at cancer conference
-
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Cogent Biosciences receives FDA breakthrough therapy designation
-
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
-
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
-
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
-
Cogent Biosciences (COGT) reports positive results from mastocytosis drug trial
-
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Adv
-
Cogent Biosciences (COGT) Secures up to $400 Million in Non-Dilutive Financing
-
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
-
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
-
Cogent Biosciences Reports First Quarter 2025 Financial Results
-
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
-
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
-
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
-
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
-
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
-
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
-
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
-
Cogent Biosciences (COGT) Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
-
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
-
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
-
Cogent Biosciences (COGT) Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
-
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
-
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
-
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
-
Cogent Biosciences (COGT) Announces Pipeline Expansion into KRAS and Poster Presentations
-
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
-
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
-
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
-
Cogent Biosciences (COGT) Reports Positive FDA Meeting and Alignment on MS2D2
-
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial
